These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31779986)

  • 1. Will new agents impact survival in AML?
    Rowe JM
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
    Stone RM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
    Estey E; Karp JE; Emadi A; Othus M; Gale RP
    Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
    Tang K; Schuh AC; Yee KW
    Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Talati C; Sweet K
    Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The growing landscape of FLT3 inhibition in AML.
    Smith CC
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):539-547. PubMed ID: 31808872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
    Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
    Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AML: New Drugs but New Challenges.
    Burnett A; Stone R
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating newer agents in the treatment of acute myeloid leukemia.
    Raj RV; Abedin SM; Atallah E
    Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Wei AH; Tiong IS
    Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Röllig C; Schliemann C; Ruhnke L; Fransecky L; Heydrich BN; Hanoun M; Noppeney R; Schäfer-Eckart K; Wendelin K; Mikesch JH; Middeke JM; Reimann M; Fiebig F; Zukunft S; Wermke M; Serve H; Platzbecker U; Müller-Tidow C; Baldus CD; Bornhäuser M
    Br J Haematol; 2024 Jun; 204(6):2254-2258. PubMed ID: 38593353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and predictions: AML in 2018.
    Rowe JM
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
    Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel Strategies to Treat Acute Myeloid Leukemia].
    Gediga MHE; Middeke JM; Ruhnke L
    Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent and combination biologics in acute myeloid leukemia.
    Richard-Carpentier G; DiNardo CD
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.